Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor...

by Blumenschein, G., Jr, Colevas, A.D, Docampo, L.C.I, Even, C., Fayette, J., Ferris, R.L, Gillison, M.L, Guigay, J., Haddad, R., Harrington, K.J, Jayaprakash, V., Kasper, S., Kiyota, N., Li, L., Licitra, L., Lynch, M., Rordorf, T., Saba, N.F, Tahara, M., Vokes, E.E, Worden, F.
Published 2018

Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study

by Antonuzzo, L., Atzori, F., Basso, U., Bracarda, S., Carella, C., Cartenì, G., Cusmai, A., D’arcangelo, M., De Giorgi, U., Deppieri, F.M, Fornarini, G., Fratino, L., Panni, S., Paolieri, F., Pipitone, S., Procopio, G., Rizzo, M., Santoni, M., Tortora, G., Zagonel, V., Zucali, P.
Published 2022

A comparison of the Food and Drug Administration’s and Health Canada’s regulatory decisions about failed confirmatory trials for oncology drugs: an observational study

by Lexchin, J.
Published 2021

Ravulizumab: Characterization and quantitation of a new C5 inhibitor using isotype specific affinity purification and high-resolution mass spectrometry

by Ladwig, P.M, Willrich, M.A.V
Published 2021

Predictive biomarkers for the efficacy of nivolumab as ≥ 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial

by Kang, Y.-K, Kim, D., Kim, J.H, Lee, S.Y, Ma, J., Park, Y.S, Ryu, M.-H
Published 2022

CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future

by Lim, M., Lin, Y.-J, Mashouf, L.A
Published 2022

Soluble PD-L1 as an early marker of progressive disease on nivolumab

by Choueiri, T.K, Freeman, G.J, Mahoney, K.M, Mcdermott, D.F, Ross-Macdonald, P., Song, L., Stephen Hodi, F., Veras, E., Wind-Rotolo, M., Yuan, L.
Published 2022

Drugs to Be Used With a Filter for Preparation and/or Administration—2019

by Galka, E., Hartke, P., Ipema, H.J, Nazari, J., Varabyeva, A., Yu, M., Zacher, J.M
Published 2021

Augmented Clearance of Nivolumab Is Associated with Renal Functions in Chronic Renal Disease Model Rats

by Enoki, Y., Hamada, A., Hayashi, Y., Matsumoto, K., Ohuchi, M., Taguchi, K., Yagishita, S., Yamada, H.
Published 2022

Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 tria...

by Adkins, D., Atiq, O., Gitau, M., Ley, J., Liu, J., Oppelt, P., Palka, K., Powell, S., Rigden, C., Spanos, W.C
Published 2021

Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients

by Bal, W., Cybulska-Stopa, B., Czarnecka, A.M, Dziura, R., Galus, Ł., Kamińska-Winciorek, G., Kempa-Kamińska, N., Kozak, K., Kubiatowski, T., Mackiewicz, J., Ostaszewski, K., Piejko, K., Rogala, P., Rutkowska, E., Rutkowski, P., Seredyńska, J., Surus-Hyla, A., Suwiński, R., Ziętek, M.
Published 2022